A302550 Stock Overview
Engages in the manufactures and supplies of medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Remed Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,790.00 |
| 52 Week High | ₩4,420.00 |
| 52 Week Low | ₩2,545.00 |
| Beta | 0.35 |
| 1 Month Change | -4.41% |
| 3 Month Change | 26.54% |
| 1 Year Change | n/a |
| 3 Year Change | -27.12% |
| 5 Year Change | 47.47% |
| Change since IPO | 21.09% |
Recent News & Updates
Here's What's Concerning About RemedLtd's (KOSDAQ:302550) Returns On Capital
Dec 16
Remed Co.,Ltd.'s (KOSDAQ:302550) 43% Price Boost Is Out Of Tune With Revenues
Nov 06Recent updates
Here's What's Concerning About RemedLtd's (KOSDAQ:302550) Returns On Capital
Dec 16Remed Co.,Ltd.'s (KOSDAQ:302550) 43% Price Boost Is Out Of Tune With Revenues
Nov 06RemedLtd's (KOSDAQ:302550) Profits Appear To Have Quality Issues
Aug 20Would RemedLtd (KOSDAQ:302550) Be Better Off With Less Debt?
Aug 12Investor Optimism Abounds Remed Co.,Ltd. (KOSDAQ:302550) But Growth Is Lacking
Jun 17Shareholder Returns
| A302550 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 0.4% | 0.7% | -1.6% |
| 1Y | n/a | -2.0% | -9.1% |
Return vs Industry: Insufficient data to determine how A302550 performed against the KR Medical Equipment industry.
Return vs Market: Insufficient data to determine how A302550 performed against the KR Market.
Price Volatility
| A302550 volatility | |
|---|---|
| A302550 Average Weekly Movement | 9.8% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A302550's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A302550's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 91 | Geun-Yong Lee | remed.kr |
Remed Co.,Ltd. engages in the manufactures and supplies of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as tinnitus, insomnia, dementia, stress, anxiety, etc. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells, and contraction and relaxation of muscles, as well as core muscle strengthening magnetic stimulation to enable building toned and shaped muscles.
Remed Co.,Ltd. Fundamentals Summary
| A302550 fundamental statistics | |
|---|---|
| Market cap | ₩116.12b |
| Earnings (TTM) | ₩4.86b |
| Revenue (TTM) | ₩23.42b |
23.9x
P/E Ratio5.0x
P/S RatioIs A302550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A302550 income statement (TTM) | |
|---|---|
| Revenue | ₩23.42b |
| Cost of Revenue | ₩11.08b |
| Gross Profit | ₩12.34b |
| Other Expenses | ₩7.48b |
| Earnings | ₩4.86b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 158.73 |
| Gross Margin | 52.70% |
| Net Profit Margin | 20.76% |
| Debt/Equity Ratio | 35.5% |
How did A302550 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 20:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Remed Co.,Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eun-Ae Cho | LS Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |
| Kwan Jun Ra | NH Investment & Securities Co., Ltd. |